Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/12115
Title: Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene
Authors: Gueiros Filho, Frederico José
Viola, Joao Paulo de Biaso
Gomes, Flávia Carvalho Alcantara;
Farina, Marco
Lins, Ulysses
Bertho, Alvaro Luiz
Wirth, Dyann F.
Lopes, Ulisses Gazos
Keywords: Leishmania mexicana
Tuberculose Resistente a Múltiplos Medicamentos
Tuberculosis Multidrug-Resistant
Membro 1 da Subfamília B de Cassetes de Ligação de ATP
ATP Binding Cassette Transporter, Subfamily B Member 1
Vimblastina
Vinblastine
Doxorrubicina
Doxorubicin
Rodamina 123
Rhodamine 123
Issue Date: Dec-1995
Abstract: A vinblastine-resistant Leishmania amazonensis cell line (RV100) which exhibits cross-resistance to the unrelated drug adriamycin, and thus is considered to be multidrug resistant (MDR), was isolated after stepwise selection with increasing concentrations of vinblastine. This phenotype was partially reverted by the calcium channel antagonist verapamil. Drug transport studies using the hydrophobic fluorescent dye rhodamine 123 demonstrated that the MDR cell line has a reduced dye accumulation due to an increased efflux. Furthermore, DNA and RNA hybridization studies demonstrated that a gene (lamdr1), homologous to ldmdr1 and lemdr1, was overexpressed and amplified within 27 kb extrachromosomal DNA circles (V-circles) in these cells. An independent cell line, RA5000, which was selected for resistance to adriamycin and was not cross-resistant to vinblastine, accumulated normal levels of rhodamine 123 and did not contain amplified DNA or overexpressed RNA of mdr-related sequences.
URI: https://ninho.inca.gov.br/jspui/handle/123456789/12115
ISSN: 0014-4894
Appears in Collections:Artigos de Periódicos da Pesquisa Experimental e Translacional



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.